November 15, 2022
Psilacetin is More Potent than Psilocybin, Study Shows
Researchers directly compared psilocybin with understudied magic mushroom molecules, and synthetic analogs such as psilacetin
Updates
September 22, 2022
CaaMTech Creates Two New Prodrugs of 4-HO-DiPT
4-HO-DiPT has been proposed as a more clinically-optimized alternative to psilocybin
September 14, 2022
CaaMTech Publishes Fundamental Research on Aeruginascin Derivatives
Aeruginascin is a naturally-occurring quaternary tryptammonium compound found in Magic Mushrooms
July 6, 2022
CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds
CaaMTech will help carry on Dr. Alexander Shulgin’s legacy by developing ASRI’s novel compounds
June 15, 2022
Mike O’Shaughnessy Joins CaamTech as General Counsel and Director of Intellectual Property
O’Shaughnessy brings decades of experience in intellectual property strategy, collaborations, and development within the life sciences and pharmaceutical industries
June 2, 2022
CaaMTech Collaboration Proves Diversity in Magic Mushroom Chemistry
A new paper published by The Leibniz Institute for Natural Product Research in collaboration with CaaMTech reveals the complex chemistry of magic mushrooms
May 9, 2022
“Minor” Magic Mushroom Compound Crystal Structure Solved
CaaMTech collaborates with UMass Dartmouth to solve crystal structure of overlooked baeocystin
March 15, 2022
CaaMTech Solves Serotonin Crystal Structure
CaaMTech scientists have solved the crystal structure of freebase serotonin for the first time
February 17, 2022
Bob Discordia Joins CaaMTech as Chief Scientific Officer
Dr. Discordia brings over 30 years of pharmaceutical industry experience to CaaMTech
November 16, 2021
CaaMTech Teams Up with University of Wyoming to Study Psychedelics as Treatments for Addiction
Scientists will assess the potential of psychedelic compounds for treating addiction
